Finance
Funding Statement
EFNA funding arises from a small number of sources, including the pharmaceutical
and medical device industries, the European Commission and others. Some
of the grants are specific for particular EFNA projects and, where possible,
we try to involve a consortium of donors for each project.
No donor, including the European Commission, has had any undue influence
of any kind over EFNA’s activities, nor are there any conflicts of
interest.
It is important to remember that EFNA is an extremely broadly-based organisation,
which attempts to improve the quality of life for people in Europe living
with neurological illness. Our projects are equally broad and tend to deal
with issues generic to all or several neurological conditions and education
rather than with specific drugs or other treatments. EFNA’s relationships
within the pharmaceutical and medical device industry are usually at the
level of government affairs and policy and our relationships with all sponsors/funders
are regulated carefully by our “Code of Practice”.
Grants
Grants are listed by donor, with the percentage of total EFNA funding
shown. These should be considered alongside funding in other years, as the
figures below merely show the ‘snapshot’ of funds received as
at 31 December in the year concerned.
The total amount of EFNA funding for each year may be found in the audited
accounts, on this website but these accounts do not include, of course,
any ‘donations in kind’ such as staff secondment. In the tables
of percentages “EFNS” is the acronym for European Federation
of Neurological Societies.
| 2008 |
| Source |
Grant/value of donation in kind |
% of Total Funding & other support |
| Novartis |
€52,873.37 |
17.14 |
| Britannia |
€ 6,473.95 |
2.10 |
| GE Healthcare |
€13,065.53 |
4.23 |
| Solvay |
€53,600.16 |
17.37 |
| TEVA |
€ 1,000.00 |
0.32 |
| GSK |
€30,689.33 |
9.95 |
| Genus Pharm |
€20,963.37 |
6.79 |
| European Commission |
€ 1,906.52 |
0.62 |
| Pfizer |
€42,580.00 |
13.80 |
| Boehringer Ingelheim |
€60,700.00 |
19.67 |
| EFNS |
€23,000.00 |
7.45 |
| Other |
€ 1,711.89 |
0.55 |
| 2007 |
| Source |
Grant/value of donation in kind |
% of Total Funding & other support |
| European Commission (Restricted) |
€3,521 |
2.08 |
| European Commission (Restricted) |
€52,070 |
30.79 |
| Boehringer (Restricted) |
€40,000 |
23.65 |
| GSK (Unrestricted) |
€28,673 |
16.95 |
| Novartis (Restricted) |
€20,209 |
11.95 |
| EFNS (Staff secondment) |
€23,000 |
13.60 |
| Other |
€1,645 |
0.97 |
| 2006 |
| Source |
% of Total Funding & other support |
| Novartis (Restricted) |
2.62 |
| Movers and Shakers (UK Charity) |
15.40 |
| GSK (Restricted) |
1.93 |
| GE Healthcare (Restricted) |
15.03 |
| GSK (Unrestricted) |
14.48 |
| Alexion Pharma |
20.21 |
| GSK (Restricted) |
15.56 |
| European Parkinson's Disease |
0.39 |
| Eli Lilly (Resticted) |
2.05 |
| EFNS (Staff secondment) |
12.07 |
| Other |
0.26 |
| 2005 |
| Source |
% of Total Funding & other support |
| Britannia Pharma (Restricted) |
1.36 |
| Valeant (Restricted) |
1.37 |
| GSK (Unrestricted) |
2.72 |
| European Commission (Restricted) |
83.49 |
| Schering (Restricted) |
3.80 |
| MSD (Restricted) |
2.76 |
| Serono (Restricted) |
0.38 |
| EFNS (Staff secondment) |
3.92 |
| Other |
0.21 |
| 2004 |
| Source |
% of Total Funding & other support |
| GSK (Unrestricted) |
9.9 |
| Novartis (Unrestricted) |
29.6 |
| Novartis (Restricted) |
24.3 |
| MSD (Unrestricted) |
9.9 |
| EFNS (Staff secondment) |
22.4 |
| Other |
3.9 |